MedTrace Logo

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

NCT00361881 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1443

Last updated 2008-08-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.

Conditions

  • Herpes Labialis

Interventions

DRUG

ME-609

Cream, dose 5 times daily during 5 days.

DRUG

acyclovir in ME-609 vehicle

Dose 5 times daily for 5 days

DRUG

Vehicle

Dose 5 times daily for 5 days

Sponsors & Collaborators

  • Medivir

    lead INDUSTRY

Principal Investigators

  • Christopher M Hull, MD

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-08-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00361881 on ClinicalTrials.gov